Zhiming Li

4PUBLICATIONS
3CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 03, 2025
Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial.

Qihua Zou, Yuchen Zhang, Hui Zhou

|Nov 27, 2023
Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era.

Peng Sun, Hang Yang, Baitian Zhao

|Nov 12, 2023
Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study.

Peng Sun, Hang Yang, Yu Wang

|Mar 27, 2023
A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer/T-cell lymphoma.

Peng Sun, Yajun Li, Cong Li

Pageof 1

Frequent Collaborators

3 joint publications

Zhiming Li

1 joint publications

Panpan Liu

1 joint publications

Qingqing Cai